OverviewSuggest Edit

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
TypePublic
Founded1963
HQMarcy-l'Étoile, FR
Websitebiomerieux.com
Employee Ratings4.2

Recent NewsAll News

Latest Updates

Employees (est.) (Sept 2020)12,000(-18%)
Revenue (FY, 2016)€2.1 B(+8%)
Share Price (Oct 2020)€134.2
Cybersecurity ratingDMore

Key People/Management at bioMerieux

Alexandre MeRieux

Alexandre MeRieux

Chairman and CEO
Michel Baguenault

Michel Baguenault

Corporate Vice President, Human Resources
Agnès Lemarchand

Agnès Lemarchand

Independent Director
Marie-Hélène Habert

Marie-Hélène Habert

Independent Director
Jean-Marc Durano

Jean-Marc Durano

Corporate Vice President, Industrial Microbiology Unit
Marie-Paule Kieny

Marie-Paule Kieny

Independent Director
Show more

bioMerieux Office Locations

bioMerieux has offices in Marcy-l'Étoile and Midrand
Marcy-l'Étoile, FR (HQ)
376 Chemin de l'Orme
Midrand, ZA
44 on Grand Central, Diagonal St, Grand Central
Show all (2)

bioMerieux Financials and Metrics

bioMerieux Revenue

Embed Graph
View revenue for all periods
bioMerieux's revenue was reported to be €2.10 b in FY, 2016 which is a 7.1% increase from the previous period.
EUR

Revenue (FY, 2016)

2.1b

Revenue growth (FY, 2015 - FY, 2016), %

7.1%

Gross profit (FY, 2016)

1.1b

Gross profit margin (FY, 2016), %

52.3%

Net income (FY, 2016)

179.2m

EBIT (FY, 2016)

282.5m

Market capitalization (2-Oct-2020)

15.9b

Closing stock price (2-Oct-2020)

134.2

Cash (31-Dec-2016)

178.6m

EV

16.1b
bioMerieux's current market capitalization is €15.9 b.
EURFY, 2014FY, 2015FY, 2016

Revenue

1.7b2.0b2.1b

Revenue growth, %

16%7%

Cost of goods sold

853.9m975.4m1.0b

Gross profit

844.5m989.2m1.1b
EURFY, 2014FY, 2015FY, 2016

Cash

119.7m147.1m178.6m

Accounts Receivable

449.3m445.1m465.8m

Inventories

299.2m355.8m404.4m

Current Assets

991.4m1.1b1.2b
EURFY, 2014FY, 2015FY, 2016

Net Income

135.5m110.3m179.2m

Cash From Operating Activities

298.3m310.0m335.6m

Purchases of PP&E

(158.1m)(208.2m)(233.0m)

Cash From Investing Activities

(502.7m)(208.0m)(257.2m)
EURFY, 2014

Debt/Equity

0.3 x

Debt/Assets

0.1 x

Financial Leverage

1.9 x
Show all financial metrics

bioMerieux Operating Metrics

FY, 2015FY, 2016

Countries

150

Facilities

19

Patents and Patent Applications

581 529
Show all operating metrics

bioMerieux Cybersecurity Score

Cybersecurity ratingPremium dataset

D

64/100

SecurityScorecard logo

bioMerieux Online and Social Media Presence

Embed Graph

bioMerieux News and Updates

Insights on the Endocrine Testing Global Market to 2027 - Featuring Abbott Laboratories, Agilent Technologies & bioMerieux Among Others

Dublin, Sept. 15, 2020 (GLOBE NEWSWIRE) -- The "Endocrine Testing - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. The publisher brings years of research experience to the 5th edition of this report. The 415-page report presents concise insig…

bioMerieux receives Emergency Use Authorization for BIOFIRE COVID-19 test

To discover all of our products for industrial microbiological control, please visit our bioMérieux Industry website.read more

bioMerieux and the Fleming Fund: working together to strengthen diagnostic capacity and tackle antimicrobial resistance in low- and middle-income countries

Institut Mérieux is committing its experience in industrial biology to serve medicine and public health across the globe.read more

Global Immunoassay Market Outlook and Forecast to 2025 - Leading Vendors are Roche Diagnostics, bioMerieux, Abbott Laboratories, Becton Dickinson & Company, and Siemens Healthineers

DUBLIN, Nov. 28, 2019 /PRNewswire/ -- The "Immunoassay Market By Products and Services (Instruments, Reagents & Kits, Software & Services), By Applications (Oncology, Infectious Disease Testing, Cardiology, Endocrinology, Autoimmune Disease, Other Applications), By End-users, By Regions -...

In Vitro Diagnostics Market 2019-2024: Global Analysis by Key Players – Alere Inc, Bayer AG, Danaher, Biomerieux

Wiseguyreports.Com Publish New Market Research Report On -“In Vitro Diagnostics Market 2019 Global Analysis, Size, Share, Trends, Opportunities and Growth, Forecast 2024” Posted via Industry Today. Follow us on Twitter @IndustryToday

Informative Report on Food Diagnostics Market 2019: with Top Leading Vendors like Biomerieux SA (France), Danaher Corporation (US), Bio-Rad Laboratories Inc. (US), Neogen Corporation (US)

The food diagnostics systems market was segmented based on the diagnostic systems and consumables essential for testing of food products. Diagnostic technologies help to detect the presence of adulterants, contaminants, and analyze nutrient composition of the food samples. Posted via Industry Today.…
Show more

bioMerieux Blogs

bioMerieux Frequently Asked Questions

  • When was bioMerieux founded?

    bioMerieux was founded in 1963.

  • Who are bioMerieux key executives?

    bioMerieux's key executives are Alexandre MeRieux, Michel Baguenault and Agnès Lemarchand.

  • How many employees does bioMerieux have?

    bioMerieux has 12,000 employees.

  • What is bioMerieux revenue?

    Latest bioMerieux annual revenue is €2.1 b.

  • What is bioMerieux revenue per employee?

    Latest bioMerieux revenue per employee is €175.3 k.

  • Who are bioMerieux competitors?

    Competitors of bioMerieux include Bio-Rad, VWR and GoHealth Urgent Care.

  • Where is bioMerieux headquarters?

    bioMerieux headquarters is located at 376 Chemin de l'Orme, Marcy-l'Étoile.

  • Where are bioMerieux offices?

    bioMerieux has offices in Marcy-l'Étoile and Midrand.

  • How many offices does bioMerieux have?

    bioMerieux has 2 offices.